Exclusive Summary

• Nurtec ODT (originator) has exceeded $1 billion in annual US sales; generic market entry is imminent, and this supplier's FDA-GMP-certified product currently under FDA review is perfectly positioned to be among the first generic entrants.
• With over 1.15 billion migraine sufferers globally and approximately 300 million experiencing frequent or chronic attacks, rimegepant addresses a critical unmet need for the 30-40% of patients who respond inadequately to triptans.
• Rimegepant 75mg ODT is the only FDA-approved CGRP antagonist indicated for both acute treatment and preventive treatment of migraine, giving it a uniquely differentiated clinical profile versus all other gepants and triptans.
• No generic version of rimegepant has been approved in the US to date, making this supplier a potential first-wave generic entrant with significant first-mover advantage once the patent licensing window opens (expected ~2026).
• US FDA GMP certification provides the highest-tier quality credential globally, serving as a strong compliance endorsement for entry into regulated markets such as Canada, Australia, EU, and select Southeast Asian markets.